Oncotelic Therapeutics - 45 Year Dividend History | OTLC
Historical dividend payout and yield for Oncotelic Therapeutics (OTLC) since 1971. The current TTM dividend payout for Oncotelic Therapeutics (OTLC) as of December 07, 2016 is $0.00. The current dividend yield for Oncotelic Therapeutics as of December 07, 2016 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.016B |
$0.000B |
|
Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting the TGF-beta2 mRNA. Mateon is conducting a Phase 2/3 clinical trial of OT-101 in patients suffering from COVID-19. In addition, the company has initiated a global Phase 4 clinical trial of ArtiShield(TM) in India, Africa, and Latin America for the treatment of COVID-19, with results expected in the 4Q20. ArtiShieldTM received marketing approval from India.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
